172. Hypophosphatasia Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 34 / Drugs : 17 - (DrugBank : 4) / Drug target genes : 3 - Drug target pathways : 6
Drugs and their primary sponsors and trial info
ALXN1850
Alexion Pharmaceuticals
2021 Phase 1 NCT04980248 United States;
Asfotas Alfa
Alexion Pharma International Sàrl
2016 Phase 4 EUCTR2015-000809-39-FR Belgium;France;Netherlands;Russian Federation;Spain;
Asfotase Alfa (ALXN1215)
Translational Research Informatics Center, Kobe, Hyogo, Japan
2014 Phase 2 NCT02456038 Japan;
Asfotase alfa
Alexion Pharma GmbH
2011 Phase 2 EUCTR2010-019850-42-DE Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
Alexion Pharma GmbH
2013 Phase 2 EUCTR2010-019850-42-GB Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2009 Phase 2 EUCTR2009-009369-32-GB United Arab Emirates;United Kingdom;United States;
Alexion Pharma International Sàrl
2013 Phase 2 EUCTR2010-019850-42-IT Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 2 EUCTR2010-019850-42-ES Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
- Phase 2 EUCTR2010-019850-42-FR Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
Alexion Pharmaceuticals
2020 Phase 4 NCT04189315 -
2019 - NCT04195763 United States;
2016 Phase 2 NCT02797821 Germany;United States;
2016 - NCT02496689 France;United States;
2010 Phase 2/Phase 3 NCT01176266 Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2010 Phase 2 NCT01163149 Canada;United States;
2009 Phase 2 NCT01205152 United Arab Emirates;United Kingdom;United States;
2009 Phase 2 NCT00952484 Canada;United States;
2008 Phase 1/Phase 2 NCT00744042 Canada;United Arab Emirates;United Kingdom;United States;
HPP study group
2014 - JPRN-UMIN000014816 Japan;
BPS804
Novartis Pharma Services AG
2011 - EUCTR2010-024013-31-DE Germany;
Novartis Pharmaceuticals
2011 Phase 2 NCT01406977 Germany;
Biochemical analysis of different bone markers.
Hvidovre University Hospital
2019 - NCT04181164 Denmark;
Cyclophosphamide
Shimane University School of Medicine
2010 Phase 2,3 JPRN-UMIN000003828 Japan;
ENB-0040
Alexion Pharma International Sarl
2009 Phase 2 NCT00894075 United States;
Alexion Pharma International Sàrl
2016 Phase 4 EUCTR2015-000809-39-FR Belgium;France;Netherlands;Russian Federation;Spain;
2013 Phase 2 EUCTR2010-019850-42-IT Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 2 EUCTR2010-019850-42-ES Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
- Phase 2 EUCTR2010-019850-42-FR Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
Enobia Canada Limited Partnership
2009 - EUCTR2008-007406-11-GB United Kingdom;
Fully human IgG2 lambda monoclonal antibody
Novartis Pharma Services AG
2011 - EUCTR2010-024013-31-DE Germany;
Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein
Alexion Pharma GmbH
2011 Phase 2 EUCTR2010-019850-42-DE Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
Alexion Pharma GmbH
2016 Phase 2 EUCTR2015-003131-35-DE Germany;United States;
Alexion Pharma International Sàrl
2016 Phase 4 EUCTR2015-000809-39-FR Belgium;France;Netherlands;Russian Federation;Spain;
Enobia Canada Limited Partnership
2009 - EUCTR2008-007406-11-GB United Kingdom;
Human recombinant tissue non-specific alkaline phosphatase fusion protein
Alexion Pharma GmbH
2013 Phase 2 EUCTR2010-019850-42-GB Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2009 Phase 2 EUCTR2009-009369-32-GB United Arab Emirates;United Kingdom;United States;
- Phase 2 EUCTR2017-003153-42-Outside-EU/EEA Canada;United States;
- Phase 2 EUCTR2017-001831-38-Outside-EU/EEA Canada;United States;
Alexion Pharma International Sàrl
2013 Phase 2 EUCTR2010-019850-42-IT Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 2 EUCTR2010-019850-42-ES Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
- Phase 2 EUCTR2010-019850-42-FR Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
- - EUCTR2015-001128-52-Outside-EU/EEA Canada;United States;
Methotrexate
Shimane University School of Medicine
2010 Phase 2,3 JPRN-UMIN000003828 Japan;
Retrospective Case Only
Alexion Pharmaceuticals
2014 - NCT02235493 United States;
Strensiq
Alexion Pharma GmbH
2011 Phase 2 EUCTR2010-019850-42-DE Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
Alexion Pharma GmbH
2016 Phase 2 EUCTR2015-003131-35-DE Germany;United States;
2013 Phase 2 EUCTR2010-019850-42-GB Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2009 Phase 2 EUCTR2009-009369-32-GB United Arab Emirates;United Kingdom;United States;
- Phase 2 EUCTR2017-003153-42-Outside-EU/EEA Canada;United States;
- Phase 2 EUCTR2017-001831-38-Outside-EU/EEA Canada;United States;
Alexion Pharma International Sàrl
2016 Phase 4 EUCTR2015-000809-39-FR Belgium;France;Netherlands;Russian Federation;Spain;
Alexion Pharmaceuticals
2021 Phase 1 NCT04980248 United States;
Asfotas Alfa
Alexion Pharma International Sàrl
2016 Phase 4 EUCTR2015-000809-39-FR Belgium;France;Netherlands;Russian Federation;Spain;
Asfotase Alfa (ALXN1215)
Translational Research Informatics Center, Kobe, Hyogo, Japan
2014 Phase 2 NCT02456038 Japan;
Asfotase alfa
Alexion Pharma GmbH
2011 Phase 2 EUCTR2010-019850-42-DE Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
Alexion Pharma GmbH
2013 Phase 2 EUCTR2010-019850-42-GB Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2009 Phase 2 EUCTR2009-009369-32-GB United Arab Emirates;United Kingdom;United States;
Alexion Pharma International Sàrl
2013 Phase 2 EUCTR2010-019850-42-IT Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 2 EUCTR2010-019850-42-ES Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
- Phase 2 EUCTR2010-019850-42-FR Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
Alexion Pharmaceuticals
2020 Phase 4 NCT04189315 -
2019 - NCT04195763 United States;
2016 Phase 2 NCT02797821 Germany;United States;
2016 - NCT02496689 France;United States;
2010 Phase 2/Phase 3 NCT01176266 Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2010 Phase 2 NCT01163149 Canada;United States;
2009 Phase 2 NCT01205152 United Arab Emirates;United Kingdom;United States;
2009 Phase 2 NCT00952484 Canada;United States;
2008 Phase 1/Phase 2 NCT00744042 Canada;United Arab Emirates;United Kingdom;United States;
HPP study group
2014 - JPRN-UMIN000014816 Japan;
BPS804
Novartis Pharma Services AG
2011 - EUCTR2010-024013-31-DE Germany;
Novartis Pharmaceuticals
2011 Phase 2 NCT01406977 Germany;
Biochemical analysis of different bone markers.
Hvidovre University Hospital
2019 - NCT04181164 Denmark;
Cyclophosphamide
Shimane University School of Medicine
2010 Phase 2,3 JPRN-UMIN000003828 Japan;
ENB-0040
Alexion Pharma International Sarl
2009 Phase 2 NCT00894075 United States;
Alexion Pharma International Sàrl
2016 Phase 4 EUCTR2015-000809-39-FR Belgium;France;Netherlands;Russian Federation;Spain;
2013 Phase 2 EUCTR2010-019850-42-IT Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 2 EUCTR2010-019850-42-ES Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
- Phase 2 EUCTR2010-019850-42-FR Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
Enobia Canada Limited Partnership
2009 - EUCTR2008-007406-11-GB United Kingdom;
Fully human IgG2 lambda monoclonal antibody
Novartis Pharma Services AG
2011 - EUCTR2010-024013-31-DE Germany;
Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein
Alexion Pharma GmbH
2011 Phase 2 EUCTR2010-019850-42-DE Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
Alexion Pharma GmbH
2016 Phase 2 EUCTR2015-003131-35-DE Germany;United States;
Alexion Pharma International Sàrl
2016 Phase 4 EUCTR2015-000809-39-FR Belgium;France;Netherlands;Russian Federation;Spain;
Enobia Canada Limited Partnership
2009 - EUCTR2008-007406-11-GB United Kingdom;
Human recombinant tissue non-specific alkaline phosphatase fusion protein
Alexion Pharma GmbH
2013 Phase 2 EUCTR2010-019850-42-GB Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2009 Phase 2 EUCTR2009-009369-32-GB United Arab Emirates;United Kingdom;United States;
- Phase 2 EUCTR2017-003153-42-Outside-EU/EEA Canada;United States;
- Phase 2 EUCTR2017-001831-38-Outside-EU/EEA Canada;United States;
Alexion Pharma International Sàrl
2013 Phase 2 EUCTR2010-019850-42-IT Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 2 EUCTR2010-019850-42-ES Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
- Phase 2 EUCTR2010-019850-42-FR Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
- - EUCTR2015-001128-52-Outside-EU/EEA Canada;United States;
Methotrexate
Shimane University School of Medicine
2010 Phase 2,3 JPRN-UMIN000003828 Japan;
Retrospective Case Only
Alexion Pharmaceuticals
2014 - NCT02235493 United States;
Strensiq
Alexion Pharma GmbH
2011 Phase 2 EUCTR2010-019850-42-DE Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
Alexion Pharma GmbH
2016 Phase 2 EUCTR2015-003131-35-DE Germany;United States;
2013 Phase 2 EUCTR2010-019850-42-GB Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
2009 Phase 2 EUCTR2009-009369-32-GB United Arab Emirates;United Kingdom;United States;
- Phase 2 EUCTR2017-003153-42-Outside-EU/EEA Canada;United States;
- Phase 2 EUCTR2017-001831-38-Outside-EU/EEA Canada;United States;
Alexion Pharma International Sàrl
2016 Phase 4 EUCTR2015-000809-39-FR Belgium;France;Netherlands;Russian Federation;Spain;